Codominant Expression of N-Acetylation and O-Acetylation Activities Catalyzed by N-Acetyltransferase 2 in Human Hepatocytes
Authors:
- Yu ZangYZYu Zang
- Timothy MoellerTMTimothy Moeller
- David W. HeinDHDavid W. Hein
- 1 August 2010
- journal article
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 334 (2) , 540-544
Abstract
Human populations exhibit genetic polymorphism in N-acetylation capacity, catalyzed by N-acetyltransferase 2 (NAT2). We investigated the relationship between NAT2 acetylator genotype and phenotype in cryopreserved human hepatocytes. NAT2 genotypes determined in 256 human samples were assigned as rapid (two rapid alleles), intermediate (one rapid and one slow allele), or slow (two slow alleles) acetylator phenotypes based on functional characterization of the NAT2 alleles reported previously in recombinant expression systems. A robust and significant relationship was observed between deduced NAT2 phenotype (rapid, intermediate, or slow) and N-acetyltransferase activity toward sulfamethazine (p < 0.0001) and 4-aminobiphenyl (p < 0.0001) and for O-acetyltransferase-catalyzed metabolic activation of N-hydroxy-4-aminobiphenyl (p < 0.0001), N-hydroxy-2-amino-3,8-dimethylimidazo[4,5-f] quinoxaline (p < 0.01), and N-hydroxy-2-amino-1-methyl-6-phenylimidazo[4,5-b] pyridine (p < 0.0001). NAT2-specific protein levels also significantly associated with the rapid, intermediate, and slow NAT2 acetylator phenotypes (p < 0.0001). As a negative control, p-aminobenzoic acid (an N-acetyltransferase 1-selective substrate) N-acetyltransferase activities from the same samples did not correlate with the three NAT2 acetylator phenotypes (p > 0.05). These results clearly document codominant expression of human NAT2 alleles resulting in rapid, intermediate, and slow acetylator phenotypes. The three phenotypes reflect levels of NAT2 protein catalyzing both N- and O-acetylation. Our results suggest a significant role of NAT2 acetylation polymorphism in arylamine-induced cancers and are consistent with differential cancer risk and/or drug efficacy/toxicity in intermediate compared with rapid or slow NAT2 acetylator phenotypes.Keywords
This publication has 40 references indexed in Scilit:
- Effect of rapid human N-acetyltransferase 2 haplotype on DNA damage and mutagenesis induced by 2-amino-3-methylimidazo-[4,5-f]quinoline (IQ) and 2-amino-3,8-dimethylimidazo-[4,5-f]quinoxaline (MeIQx)Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2010
- Differences between human slow N-acetyltransferase 2 alleles in levels of 4-aminobiphenyl-induced DNA adducts and mutationsMutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2009
- Role of human CYP1A1 and NAT2 in 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine-induced mutagenicity and DNA adductsXenobiotica, 2009
- Manganese Superoxide Dismutase V16A Single-Nucleotide Polymorphism in the Mitochondrial Targeting Sequence Is Associated with Reduced Enzymatic Activity in Cryopreserved Human HepatocytesDNA and Cell Biology, 2009
- Systemic Functional Expression of N-Acetyltransferase Polymorphism in the F344 Nat2 Congenic RatDrug Metabolism and Disposition, 2008
- 2-Amino-3,8-Dimethylimidazo-[4,5-f]Quinoxaline–Induced DNA Adduct Formation and Mutagenesis in DNA Repair–Deficient Chinese Hamster Ovary Cells Expressing Human Cytochrome P4501A1 and Rapid or Slow AcetylatorN-Acetyltransferase 2Cancer Epidemiology, Biomarkers & Prevention, 2007
- Functional characterization of single-nucleotide polymorphisms and haplotypes of human N-acetyltransferase 2Carcinogenesis, 2007
- N- and O-acetylation of aromatic and heterocyclic amine carcinogens by human monomorphic and polymorphic acetyltransferases expressed in COS-1 cellsBiochemical and Biophysical Research Communications, 1992
- Acetylator genotype and arylamine-induced carcinogenesisBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 1988
- Genetic Control of Isoniazid Metabolism in ManBMJ, 1960